Diagnosis, Emerging Therapies, and Biomarkers in Ovarian Cancer: Shaping the Future of Clinical Practice
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Obstetrics & Gynecology".
Deadline for manuscript submissions: 31 August 2025 | Viewed by 84
Special Issue Editor
Special Issue Information
Dear Colleagues,
Globally, ovarian cancer ranks sixth among malignant tumors and fifth as a cause of cancer-related mortality in women.
Despite the progress, due to the absence of specific early symptoms, effective screening tests, and characteristic peritoneal spread, 75% of patients are diagnosed in the advanced stages and most of these patients relapse.
Standard therapy involves cytoreductive surgery followed by chemotherapy, but the poor prognosis and the attention to the genetic landscape have driven interest in alternative therapies such as targeted molecular agents that have demonstrated efficacy in both mutated and non-mutated patients.
In this Special Issue, we welcome authors to submit papers (reviews or clinical trials) on the clinical advances in ovarian cancer in terms of both diagnosis and medical and surgical treatments, and how these aspects are changing due to the molecular discoveries and biomarkers in the era of precision medicine.
Dr. Daniela Luvero
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ovarian cancer
- PARPi
- targeted therapies
- BRCA mutation
- HRD status
- precision oncology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
